Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research

Exagen (NASDAQ:XGN) had its target price trimmed by BTIG Research from $10.00 to $9.00 in a report released on Tuesday morning, MarketBeat.com reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently commented on XGN. TD Cowen cut their target price on shares of Exagen from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, February 24th. B. Riley Financial reaffirmed a “buy” rating and issued a $8.00 price target (down from $18.00) on shares of Exagen in a research note on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. Finally, William Blair reissued an “outperform” rating on shares of Exagen in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Exagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.29.

Exagen Stock Down 3.8%

XGN stock opened at $3.25 on Tuesday. The company has a market capitalization of $73.65 million, a P/E ratio of -3.53 and a beta of 1.88. The firm’s fifty day simple moving average is $4.24 and its 200-day simple moving average is $7.53. The company has a debt-to-equity ratio of 1.35, a current ratio of 4.08 and a quick ratio of 4.08. Exagen has a 12 month low of $2.80 and a 12 month high of $12.23.

Insider Buying and Selling at Exagen

In related news, CEO John Aballi sold 15,698 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total transaction of $56,826.76. Following the transaction, the chief executive officer directly owned 687,299 shares in the company, valued at approximately $2,488,022.38. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Exagen

Several hedge funds and other institutional investors have recently made changes to their positions in XGN. FourWorld Capital Management LLC acquired a new stake in Exagen during the second quarter worth approximately $1,456,000. Citizens Financial Group Inc. RI purchased a new stake in Exagen during the 2nd quarter valued at approximately $472,000. Calamos Advisors LLC acquired a new stake in shares of Exagen during the second quarter worth $526,000. Kennedy Capital Management LLC lifted its stake in shares of Exagen by 5.3% in the 2nd quarter. Kennedy Capital Management LLC now owns 310,721 shares of the company’s stock worth $2,169,000 after acquiring an additional 15,568 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in Exagen in the second quarter valued at about $217,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

Trending Headlines about Exagen

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Record revenue and test‑volume growth: Exagen reported record full‑year total revenue, higher AVISE® CTD average selling price and over 11% full‑year test volume growth, supporting longer‑term commercial progress. Exagen press release
• Positive Sentiment: Q4 revenue slightly beat estimates: Quarterly revenue of $16.63M topped consensus ($16.46M), indicating demand held up despite ongoing losses. Zacks article
• Neutral Sentiment: EPS in line with expectations: GAAP loss was $0.20 per share, matching consensus, so the quarter contained no EPS surprise that might immediately reverse sentiment. Zacks article
• Neutral Sentiment: Analyst rating remains a Buy but PT trimmed: BTIG kept a Buy rating but cut its price target from $10 to $9 — the lower target tempers upside expectations even though the rating is positive. StreetInsider note
• Negative Sentiment: FY2026 revenue guidance below consensus: Management guided revenue to $70.0M–$73.0M versus a ~$74M consensus, which likely triggered investor disappointment about near‑term growth trajectory. Exagen press release
• Negative Sentiment: Rising short interest: Short interest increased ~21% in February to about 1.07M shares (~5.4% of float), suggesting growing bearish positioning that can amplify downside pressure. (Internal short‑interest update)
• Negative Sentiment: Weak profitability and technicals: The company remains unprofitable (negative net margin and ROE), has elevated debt-to-equity, and the shares trade below the 50‑ and 200‑day moving averages — factors that reduce investor conviction near term. Yahoo highlights

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.